IP Library › Granted Patent US 12,409,309
Granted Patent B2
US 12,409,309 · App. 17/055,757 · Granted Sep 9, 2025

Connector assemblies

Inventors: Casey Tyler Hebert (Tempe, AZ); Mark Nicholas Wright (Gilbert, AZ); Brandon David Simmons (Tempe, AZ); Christopher Dean Drobnik (Wauconda, IL)
Assignee: Bard Peripheral Vascular, Inc.
A61M39/1011A61K51/00A61N5/1007A61M25/0097A61M2039/1072A61M2039/1077A61M2205/0216A61N2005/1021
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,409,309
App. No.
17/055,757
Granted
Sep 9, 2025
Kind
B2
Abstract

In one aspect, a connector assembly includes a delivery conduit defining a conduit lumen and a securable connector configured to secure the delivery conduit to a medical device hub defining a medical device hub lumen. The conduit lumen includes a constant diameter region along a portion of the delivery conduit and a transition region extending from the delivery conduit to the distal end. A transition region diameter of the transition region gradually increases from the constant diameter region to a distal end of the delivery conduit. The securable connector is coupled to an outer surface of the delivery conduit and is slidable along a portion thereof. The securable connector is configured to receive the medical device hub. The securable connector is secured relative to the delivery conduit so as to fluidically couple the conduit lumen with the medical device hub lumen.

Claims (34)

1. A connector assembly comprising:

a delivery conduit defining a lumen extending between a proximal end and a distal end,

a tube positioned within the lumen of the delivery conduit and defining a conduit lumen, and

a securable connector configured to secure the delivery conduit to a medical device hub defining a medical device hub lumen and an internal surface, wherein:

the conduit lumen comprises a constant diameter region along a portion of the delivery conduit between the proximal end and the distal end and a transition region from the delivery conduit to the distal end, wherein:

a leading edge of the transition region is obliquely angled relative to a longitudinal axis of the conduit lumen

a transition region diameter of the transition region increases from the constant diameter region to the distal end of the delivery conduit, such that the transition region has a bell shaped taper and the transition region diameter is configured to be approximately equal to a diameter of the medial device hub lumen at a position where the transition region engages the medical device hub;

the securable connector is coupled to an outer surface of the delivery conduit and is slidable along a portion thereof;

the securable connector is configured to receive the medical device hub such that the medical device hub is positioned between the surface of the delivery conduit and the securable connector; and

the securable connector is secured relative to the delivery conduit so as to fluidically couple the conduit lumen with the medical device hub lumen.

2. The connector assembly of claim 1 , further comprising a conformable material configured to be disposed between the outer surface of the delivery conduit and the internal surface of the medical device hub.

3. The connector assembly of claim 2 , wherein the conformable material comprises a thermoplastic elastomer, a thermoplastic vulcanizate, silicone, urethane, polypropylene, or combinations thereof.

4. The connector assembly claim 1 , wherein the delivery conduit comprises a first port fluidically coupled to the constant diameter region of the conduit lumen; and a second port fluidically coupled to the constant diameter region of the conduit lumen at a non-zero angle relative to the first port.

5. The connector assembly of claim 1 , wherein the delivery conduit comprises a second transition region extending between the proximal end of the delivery conduit and the constant diameter region, wherein the second transition region comprises a transition region diameter that gradually decreases from the proximal end of the delivery conduit to the constant diameter region.

6. The connector assembly of claim 1 , wherein the delivery conduit is formed from a material comprising polycarbonate, polyethylene, polyethylene terephthalate, titanium, aluminum, stainless steel, copper, polyether block amide, or combinations thereof.

7. The connector assembly of claim 1 , wherein the outer surface of the delivery conduit defines a recessed region, and the securable connector is positioned within the recessed region and configured to slide along a length of the recessed region.

8. The connector assembly of claim 1 , wherein the securable connector comprises a luer locking mechanism comprising an internal thread configured to receive an external thread located on an outer surface of the medical device hub.

9. The connector assembly of claim 1 , wherein the connector assembly is configured to deliver radioembolization fluids, chemoembolization fluids, bland embolization fluids, scout doses, or combinations thereof.

10. The connector assembly of claim 1 , further comprising the medical device hub.

11. The connector assembly of claim 1 , wherein an interface of the transition region and the medical device hub is configured to prevent the formation of turbulent flow at a distal end of the transition region.

12. The connector assembly of claim 1 , wherein the entire transition region has a non-linear taper.

13. The connector assembly of claim 1 , wherein the delivery conduit contacts a wall of the of the medical device hub at two or more discrete locations and wherein the delivery conduit is spaced away from the medical device hub between the two or more discrete locations.

14. A connector assembly comprising:

a delivery conduit defining a lumen extending between a proximal end and a distal end,

a tube positioned within the lumen of the delivery conduit and defining a conduit lumen, and

a securable connector configured to secure the delivery conduit to a medical device hub defining a medical device hub lumen and an internal surface, wherein:

the conduit lumen comprises a constant diameter region along a portion of the delivery conduit between the proximal end and the distal end and a transition region from the delivery conduit to the distal end;

a transition region diameter of the transition region increases from the constant diameter region to the distal end of the delivery conduit, such that the transition region diameter is configured to be approximately equal to a diameter of the medial device hub lumen at a position where the transition region engages the medical device hub;

the securable connector is coupled to an outer surface of the delivery conduit and is slidable along a portion thereof;

the securable connector is configured to receive the medical device hub such that the medical device hub is positioned between the surface of the delivery conduit and the securable connector; and

the securable connector is secured relative to the delivery conduit so as to fluidically couple the conduit lumen with the medical device hub lumen.

15. The connector assembly of claim 14 , wherein the delivery conduit contacts a wall of the of the medical device hub at two or more discrete locations and wherein the delivery conduit is spaced away from the medical device hub between the two or more discrete locations.

16. The connector assembly of claim 14 , wherein the tube extends past the distal end of the delivery conduit.

17. The connector assembly of claim 14 , wherein the tube is spaced away from an internal surface of the delivery conduit.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 16, 2020
From: HEBERT, CASEY TYLER; WRIGHT, MARK NICHOLAS; SIMMONS, BRANDON DAVID; DROBNIK, CHRISTOPHER D.
To: C.R. BARD, INC.
Reel/Frame 054376/0991 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 16, 2020
From: C.R. BARD, INC.
To: BARD PERIPHERAL VASCULAR, INC.
Reel/Frame 054377/0004 →
Continuity (3)
Provisional Application 62673632 · May 18, 2018
Provisional Application 62673628 · May 18, 2018
Related Publication 20210236795A1 · Aug 5, 2021
References Cited (116)
US 4313440A · Ashley · 1982 [cited by applicant]
US 5125915A · Berry · 1992 [cited by examiner]
US 5478323A · Westwood et al. · 1995 [cited by applicant]
US 5496284A · Waldenburg · 1996 [cited by applicant]
US 5620427A · Werschmidt et al. · 1997 [cited by applicant]
US 6152913A · Feith et al. · 2000 [cited by applicant]
US 6508807B1 · Peters · 2003 [cited by applicant]
US 6606370B1 · Kasprowicz · 2003 [cited by applicant]
US 6629962B2 · Correa · 2003 [cited by examiner]
US 6723074B1 · Halseth · 2004 [cited by applicant]
US 7083605B2 · Miyahara · 2006 [cited by applicant]
US 7713239B2 · Uber, III et al. · 2010 [cited by applicant]
US 20010021826A1 · Winkler · 2001 [cited by applicant]
US 20020000253A1 · Fillmore et al. · 2002 [cited by applicant]
US 20030153897A1 · Russo · 2003 [cited by applicant]
US 20030201639A1 · Korkor · 2003 [cited by examiner]
US 20030208165A1 · Christensen et al. · 2003 [cited by applicant]
US 20040111078A1 · Miyahara · 2004 [cited by applicant]
US 20040258614A1 · Line et al. · 2004 [cited by applicant]
US 20050085685A1 · Barbut · 2005 [cited by applicant]
US 20060033334A1 · Weber · 2006 [cited by examiner]
US 20060064159A1 · Porter · 2006 [cited by examiner]
US 20060091329A1 · Eguchi · 2006 [cited by applicant]
US 20060293552A1 · Polsinelli et al. · 2006 [cited by applicant]
US 20070129591A1 · Yanke et al. · 2007 [cited by applicant]
US 20070141339A1 · Song et al. · 2007 [cited by applicant]
US 20080058719A1 · Edwards et al. · 2008 [cited by applicant]
US 20080103564A1 · Burkinshaw et al. · 2008 [cited by applicant]
US 20080200747A1 · Wagner et al. · 2008 [cited by applicant]
US 20080287920A1 · Fangrow et al. · 2008 [cited by applicant]
US 20090018498A1 · Chiu et al. · 2009 [cited by applicant]
US 20090092677A1 · Richard · 2009 [cited by applicant]
US 20090232586A1 · Diodati et al. · 2009 [cited by applicant]
US 20100063481A1 · Hoffman · 2010 [cited by examiner]
US 20100084585A1 · Prosser · 2010 [cited by applicant]
US 20120190976A1 · Kleinstreuer · 2012 [cited by applicant]
US 20120201726A1 · Pearcy et al. · 2012 [cited by applicant]
US 20120209057A1 · Siess · 2012 [cited by applicant]
US 20130165899A1 · Haueter et al. · 2013 [cited by applicant]
US 20130317277A1 · Lemer · 2013 [cited by applicant]
US 20130331692A1 · Mouri · 2013 [cited by examiner]
US 20140046295A1 · Uber, III et al. · 2014 [cited by applicant]
US 20140163302A1 · Fox et al. · 2014 [cited by applicant]
US 20140207178A1 · Chomas et al. · 2014 [cited by applicant]
US 20140236093A1 · Eggert et al. · 2014 [cited by applicant]
US 20140257233A1 · Cowan · 2014 [cited by applicant]
US 20140276651A1 · Schultz · 2014 [cited by examiner]
US 20150273089A1 · Gray · 2015 [cited by applicant]
US 20150285282A1 · Weitz et al. · 2015 [cited by applicant]
US 20160296740A1 · Adams et al. · 2016 [cited by applicant]
US 20160325047A1 · Vedrine et al. · 2016 [cited by applicant]
US 20160331853A1 · Taub · 2016 [cited by applicant]
US 20160331998A1 · Hoffman et al. · 2016 [cited by applicant]
US 20170065732A1 · Srinivas et al. · 2017 [cited by applicant]
US 20170120032A1 · Miyazaki et al. · 2017 [cited by applicant]
US 20170151357A1 · Cade · 2017 [cited by applicant]
US 20170189569A1 · Souresrafil et al. · 2017 [cited by applicant]
US 20170238951A1 · Yang et al. · 2017 [cited by applicant]
US 20170304151A1 · Van Den Berg et al. · 2017 [cited by applicant]
CN 106232173A · 2016 [cited by applicant]
DE 3035290A1 · 1982 [cited by applicant]
DE 4318101A1 · 1994 [cited by applicant]
EP 0795342A2 · 1997 [cited by applicant]
EP 2179758A2 · 2010 [cited by applicant]
FR 2917981A1 · 2009 [cited by applicant]
JP H09327519A · 1997 [cited by applicant]
JP 2002543894A · 2002 [cited by examiner]
JP 2003210574A · 2003 [cited by applicant]
JP 2006017660A · 2006 [cited by applicant]
NZ 588125A · 2012 [cited by applicant]
WO 2007008511A2 · 2007 [cited by applicant]
WO 2009039203A2 · 2009 [cited by applicant]
WO 2011014562A1 · 2011 [cited by applicant]
WO 2012006555A1 · 2012 [cited by applicant]
WO 2012118687A1 · 2012 [cited by applicant]
WO 2013153722A1 · 2013 [cited by applicant]
WO 2014165058A1 · 2014 [cited by applicant]
WO 2015173612A1 · 2015 [cited by applicant]
WO 2016049685A1 · 2016 [cited by applicant]
WO 2016161346A1 · 2016 [cited by applicant]
WO 2017034965A1 · 2017 [cited by applicant]
WO 2017053398A1 · 2017 [cited by applicant]
WO 2017157974A1 · 2017 [cited by applicant]
WO 2019006099A1 · 2019 [cited by applicant]
Office Action dated Jan. 5, 2023 pertaining to Chinese Office Action 201980042280.3. [cited by applicant]
Office Action dated Oct. 19, 2022, pertaining to Chinese Office Action 201980042280.3. [cited by applicant]
Chiesa, C. et al.; A dosimetric treatment planning strategy in radioembolization of hepatocarcinoma with 90Y glass microspheres; The Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 56, No. 6; Dec. 1, 2… [cited by applicant]
Chiesa, C. et al.; Radioembolization of hepatocarcinoma with 90Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology; European Journal of Nuclear Medicine… [cited by applicant]
Spreafico, C. et al.; The dosimetric importance of the number of 90Y microspheres in liver transarterial radioembolizaiton (TARE); European Journal of Nuclear Medicine and Molecular Imaging, Springer Verlag, Heidelberg,… [cited by applicant]
International Search Report and Written Opinion dated Aug. 1, 2019 pertaining to International Application No. PCT/US2019/032983. [cited by applicant]
International Search Report and Written Opinion dated Dec. 13, 2019 pertaining to International Application No. PCT/US2019/032987. [cited by applicant]
International Search Report and Written Opinion dated Oct. 16, 2019 pertaining to International Application No. PCT/US2019/032955. [cited by applicant]
International Search Report and Written Opinion dated Jul. 23, 2019 pertaining to International Application No. PCT/US2019/032950. [cited by applicant]
International Search Report and Written Opinion dated Sep. 24, 2019 pertaining to International Application No. PCT/US2019/033011. [cited by applicant]
International Search Report and Written Opinion dated Jul. 26, 2019 pertaining to International Application No. PCT/US2019/032965. [cited by applicant]
International Search Report and Written Opinion dated Jul. 29, 2019 pertaining to International Application No. PCT/US2019/032954. [cited by applicant]
International Search Report and Written Opinion dated Aug. 7, 2019 pertaining to International Application No. PCT/US2019/032986. [cited by applicant]
Arepally, A.; Quantification and Reduction of Reflux during Embolotherapy Using an Antireflux Catheter and Tantalum Microspheres: Ex Vivo Analysis; J Vasc Interv Radiol; 2013; 24:575-580. [cited by applicant]
Chung, J. et al.; Novel use of the Surefire antireflux device in subtotal splenic embolization; Journal of Vascular Surgery Cases; Dec. 1, 2015; pp. 242-245; vol. 1, No. 4. [cited by applicant]
Ho, S. et al; Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer; European Journal of Nuclear Medicine, Springer, Berlin, Heidelberg… [cited by applicant]
Hospital Clinics et al.; Y-90 MicroSpheres (SIRSpheres) for treatment of hepatocellular carcinoma; Mar. 1, 2017. [cited by applicant]
Morshedi, M. et al.; Yttrium-90 Resin Microsphere Radioembolization Using an Antireflux Catheter: An Alternative to Traditional Coil Embolization for Nontarget Protection; Cardiovasc Intervent Radiol; 2015; 38:381-38; S… [cited by applicant]
Sirtex Medical Limited: Sirtex Medical Products Pty Ltd SIR-Spheres (Ytttrium-90 Microspheres); Apr. 1, 2005. [cited by applicant]
Theragenics Corp.; Therasphere IDOC TM; Aug. 4, 2015. [cited by applicant]
Tong, A. et al; Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry; British Journal of Radiology; vol. 89, No. 1062; Jun. 1, 2016. [cited by applicant]
US FDA; Theresphere IDOC—Humanitarian Device Exemption (HDE); Sep. 14, 2015. [cited by applicant]
Westcott, M. et al.; The development, commercialization, and clinical context of yttrium-90 radiolabeled resin and glass microspheres; Advances in Radiation Oncology; 2016; vol. 1; pp. 351-364. [cited by applicant]
Sirtex Medical Limited; SMAC-SIR-Spheres Microspheres Activity Calculator; May 6, 2018. [cited by applicant]
Office Action dated May 25, 2022, pertaining to Chinese Office Action 201980042280.3. [cited by applicant]
Evidence 1: “SIFIC Hospital Infection Prevention and Control Supplies Guidelines 2014-2015”, Hu Bijie et al., p. 233, Shanghai Science and Technology Press, May 2014. [cited by applicant]
Evidence 2: “Clinical Nursing Teaching in Internal Medicine”, Wang Xining et al., p. 113, Tianjin Science and Technology Translation and Publishing Company, Aug. 2010. [cited by applicant]
Office Action dated Apr. 19, 2023 pertaining to Chinese Application 201980042280.3. [cited by applicant]
Examination Report dated Nov. 15, 2023 pertaining to NZ 771146 filed May 17, 2019. [cited by applicant]
JP Office Action dated Apr. 18, 2024 pertaining to JP application No. 2023-107037 filed Jun. 29, 2023. [cited by applicant]
Examination Report dated May 3, 2024 pertaining to New Zealand Patent Application No. 771146 filed Dec. 15, 2020. [cited by applicant]
JP Notice of Allowance dated Sep. 3, 2024 pertaining to JP application 2023-107037 filed Jun. 29, 2023. [cited by applicant]